SPY417.26+1.39 0.33%
DIA341.86+1.53 0.45%
IXIC14,052.34+13.58 0.10%

BRIEF-Adagene Announces First Patients Dosed In Global Phase 1 Clinical Trial Of Adg126, Lead Safebody™ Program

· 03/16/2021 08:57
BRIEF-Adagene Announces First Patients Dosed In Global Phase 1 Clinical Trial Of Adg126, Lead Safebody™ Program

- Adagene Inc ADAG.O:

  • ADAGENE ANNOUNCES FIRST PATIENTS DOSED IN GLOBAL PHASE 1 CLINICAL TRIAL OF ADG126, LEAD SAFEBODY™ PROGRAM

Source text for Eikon: ID:nGNX9tG41S

Further company coverage: ADAG.O


((Reuters.Briefs@thomsonreuters.com;))